Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00655278
Other study ID # T2000-0639
Secondary ID
Status Terminated
Phase Phase 2
First received April 3, 2008
Last updated December 19, 2013
Start date August 2007
Est. completion date December 2009

Study information

Verified date November 2013
Source Taro Pharmaceuticals USA
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

This study will evaluate the safety and efficacy of T2000 when used to treat patients with moderate to severe essential tremor over an 18 month period.


Description:

Essential tremor (ET) is a common form of involuntary shaking not related to Parkinson's disease. The medications that are currently used to treat ET work in a small proportion of patients and provide only partial improvement in symptoms. Use of these current medications is also limited by side-effects in many patients.

T2000 is a medication currently under development for the treatment of essential tremor. Although T2000 is a new medication, it belongs to a class of medications that has been used for many years for the treatment of a variety of medical conditions. In previous studies, T2000 appeared to be effective in controlling symptoms of ET and some patients with severe ET had major improvements in tremor. In some patients T2000 was well tolerated for periods up to 5 months and the minimal side-effects seen were those that would be expected for medications in this class.

The current study will evaluate the safety and efficacy of T2000 in patients with moderate to severe essential tremor. Patients will receive doses of T2000 beginning at 600 mg a day, followed by 800 mg a day and up to 1000 mg a day. The total duration of treatment will be 18 months. Patient's tremor and neurological examination will be monitored throughout the study.


Recruitment information / eligibility

Status Terminated
Enrollment 5
Est. completion date December 2009
Est. primary completion date November 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

Patients will be enrolled following completion of a dose escalation trial (such as T2000-0533)

- Confirmed essential tremor by NIH criteria

- Significant functional activity limitation due to ET

- Patients who have failed, are inadequately treated or cannot tolerate alternative treatments for ET as well as treatment naïve patients who have considered but declined alternative treatment

Exclusion Criteria:

- Patients adequately controlled without side effects on a current ET treatment

- Pregnant patients or patients who may become pregnant during the study

- Patients with other medical conditions that may cause tremor, such as Parkinson's disease or active hyperthyroidism

- Patients taking medications that might produce tremor or interfere with the evaluation of tremor such as CNS-stimulants or beta-blockers

- Patients who must take medications that alter liver metabolism as well as patients with liver disease or coagulation disorders

- Patients with seizure disorders

- Patients with a history of allergy or hypersensitivity reaction to barbiturates or other related medications, such as phenobarbital or phenytoin

- Patient with significant general medical or clinical laboratory abnormalities

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
T2000
T2000 at previous most effective, well-tolerated dose (600-1000mg daily)

Locations

Country Name City State
Canada Investigator Site London Ontario
Canada Investigator Site Ottawa Ontario
Canada Investigator Site Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
Taro Pharmaceuticals USA

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Melmed C, Moros D, Rutman H. Treatment of essential tremor with the barbiturate T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid). Mov Disord. 2007 Apr 15;22(5):723-7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Effect of treatment on tremor will be measured by a tremor scale as well as by assessment of functional activity with specific tasks. Up to 18 months No
Secondary Safety parameters including neurological examination, blood tests and EKG will be monitored throughout the treatment period and during withdrawal of the medication. Up to 18 months Yes
See also
  Status Clinical Trial Phase
Withdrawn NCT05381688 - VIM DBS Respiratory Modulation: N-of-1 Trial
Recruiting NCT05101161 - Neurofeedback Using Implanted Deep Brain Stimulation Electrodes N/A
Completed NCT02277106 - Evaluate SAGE-547 in Participants With Essential Tremor Phase 2
Recruiting NCT05769933 - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Terminated NCT02678429 - Atlas Predicted DBS Settings in Essential Tremor N/A
Terminated NCT02894567 - Evaluation of Directional Recording and Stimulation Using spiderSTN N/A
Completed NCT02523807 - Tremor Monitoring Device N/A
Active, not recruiting NCT02255929 - Gamma Knife Radiosurgery for Treatment of Essential Tremor N/A
Completed NCT01223144 - Decision-making and Emotion Recognition in Essential Tremor N/A
Completed NCT00906412 - Ventrointermediate Nucleus (VIM DBS) and Working Memory N/A
Recruiting NCT05214222 - Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma Phase 2
Completed NCT03051178 - Wearable Sensor for Responsive DBS for ET N/A
Recruiting NCT03795935 - Relief From Side Effects: Clinical Use of Electrodes With Direction N/A
Not yet recruiting NCT06036368 - Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson's Disease and Essential Tremor N/A
Recruiting NCT05897775 - Coordinated Reset Deep Brain Stimulation for Essential Tremor Phase 1
Recruiting NCT05968976 - Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET N/A
Completed NCT06314139 - Tolerability and Efficacy of Continuous Theta-burst Stimulation for Essential Tremor: A Randomized Study. N/A
Recruiting NCT04501133 - Sensory-specific Peripheral Stimulation for Tremor Management N/A
Active, not recruiting NCT03560622 - Functional Neuroimaging Feedback for Focused Ultrasound Thalamotomy N/A
Completed NCT00368199 - Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes N/A